The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: Potential for selective tumour blood flow modification

British Journal of Cancer

Volumn 93, Issue 1, 2005, Pages 98-106

  Cemazar, M ^a,c   Wilson, I ^a   Prise, V E ^a   Bell, K M ^a   Hill, S A ^a   Tozer, G M ^a,b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Blood flow; Endothelin 1; ET A and ETB receptors distribution; ETB agonist IRL 1620; Rat carcinosarcoma; Vascular resistance

Indexed keywords

ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR AGONIST; IODOPHENAZONE; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; ENDOTHELIN; PEPTIDE FRAGMENT; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CARCINOSARCOMA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BINDING SITE; DRUG EFFECT; DRUG SELECTIVITY; ERYTHROCYTE KINETICS; HEART RATE; LASER DOPPLER FLOWMETRY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR UPREGULATION; TISSUE BLOOD FLOW; TUMOR BLOOD FLOW; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR RESISTANCE; VASOCONSTRICTION; ANIMAL; BLOOD PRESSURE; DRUG POTENTIATION; PATHOLOGY; VASCULARIZATION;

ANIMALS; BLOOD PRESSURE; CARCINOSARCOMA; ENDOTHELINS; HEART RATE; MALE; PEPTIDE FRAGMENTS; RATS; RECEPTOR, ENDOTHELIN B; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS;

EID: 23044437711     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602672     Document Type: Article

References (33)

1. Bagnato A, Salani D, Di Castr V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG (1999) Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for and autocrine role in tumor growth. Cancer Res 59: 720-727
2. Bell KM, Chaplin DJ, Poole BA, Prise VE, Tozer GM (1999) Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620. Int J Cancer 80: 295-302
3. Bell KM, Prise VE, Chaplin DJ, Tozer GM (1995) Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor. Cardiovasc Pharmacol 26(Suppl 3): S222-S225
4. Bell KM, Prise VE, Chaplin DJ, Tozer GM (1996) Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma. Br J Cancer Suppl 27: S161-S163
5. Bell KM, Prise VE, Chaplin DJ, Wordsworth S, Tozer GM (1997) Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats. Int J Cancer 73: 283-289
6. Bell KM, Tozer GM, Poole B, Prise VE, Chaplin DJ (1998) Spatial response of the HSN rat tumour to the endothelin B (ETB) receptor agonist IRL 1620: comparison to ETB receptor distribution. Proceedings of the 20th European conference on microcirculation Paris, France. International Proceeding Division, Manduzzi Editore, pp 19-23
7. Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1: 453-458
8. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416
9. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
10. Chaplin DJ, Hill SA, Bell KM, Tozer GM (1998) Modification of tumor blood flow: current status and future directions. Sem Radiat Oncol 8: 151-163
11. Davenport AP (2002) International union of pharmacology. XXIX update on endothelin receptor nomenclature. Pharmacol Rev 54: 219-226
12. Egidy G, Eberl LP, Valdenaire O, Irmler M, Majdi R, Diserens AC, Fontana A, Janzer RC, Pinet F, Juillerat-Jeanneret L (2000) The endothelin system in human glioblastoma. Lab Invest 80: 1681-1689
13. Glantz SA (2002) Primer of Biostatistics. New York: McGraw-Hill
14. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR (2004) A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 64: 2461-2468
15. Haynes WG, Webb DJ (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852-854
16. Hudlicka O (1998) Is physiological angiogenesis in skeletal muscle regulated by changes in microcirculation? Microcirculation 5: 7-23
17. Just A, Olson AJ, Arendshorst WJ (2004) Dual constrictor and dilator actions of ET(B) receptors in the rat renal microcirculation: interactions with ET(A) receptors. Am J Physiol Renal Physiol 286: F660-F668
18. Kety SS (1960) Theory of blood-tissue exchange and its application to measurement of blood flow. Methods Med Res 8: 223-227
19. Kurbel S, Kurbel B, Kovacic D, Sulava D, Krajina Z, Dmitrovic B, Sokcevic M (1999) Endothelin-secreting tumours and the idea of the pseudo-ectopic hormone secretion in tumours. Med Hypotheses 52: 329-333
20. Matsuura T, Yukimura T, Kim S, Miura K, Iwao H (1996) Selective blockade of endothelin receptor subtypes on systemic and renal vascular responses to endothelin-1 and IRL1620, a selective endothelin ETB-receptor agonist, in anesthetized rats. Jpn J Pharmacol 71: 213-222
21. Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116
22. Nelson JB (2001) Endothelin receptor antagonists in the treatment of prostate cancer. Prostate 49: 91-92
23. Ohlstein EH, Elliott JD, Feuerstein GZ, Ruffolo Jr RR (1996) Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets. Med Res Rev 16: 365-390
24. Ozawa Y, Hasegawa T, Tsuchiya K, Yoshizumi M, Tamaki T (2003) Effect of endothelin-1 (1-31) on the renal resistance vessels. J Med Invest 50: 87-94
25. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH (2001) Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61: 4716-4722
26. B receptors in ET-1-induced changes in blood flow to the rat breast tumor. Cancer Chemother Pharmacol 51: 21-28
27. Russell FD, Skepper JN, Davenport AP (1998) Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin converting enzyme. Circ Res 83: 314-321
28. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, Grégoire V, Balligand JL, Feron O (2004) Endothelin-1 is a critical mediator of myogenic tone in the tumor arterioles: implications for cancer treatment. Cancer Res 64: 3209-3214
29. Stjernquist M (1998) Endothelins - vasoactive peptides and growth factors. Cell Tissue Res 292: 1-9
30. Thorpe PE, Chaplin DJ, Blakey DC (2003) The first international conference on vascular targeting: meeting overview. Cancer Res 63: 1144-1147
31. Tozer GM, Shaffi KM (1993) Modification of tumour blood flow using the hypertensive agent, angiotensin II. Br J Cancer 67: 981-988
32. Tozer GM, Shaffi KM, Prise VE, Bell KM (1996) Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: relationship to receptor distribution. Int J Cancer 65: 658-663
33. Tozer GM, Shaffi KM, Prise VE, Cunningham VJ (1994) Characterisation of tumour blood flow using a 'tissue-isolated' preparation. Br J Cancer 70: 1040-1046